GANX Gain Therapeutics, Inc.

Gain Therapeutics is redefining drug discovery with its See-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/18/2021
Outstanding shares:  11,879,743
Average volume:  134,469
Market cap:   $80,188,265
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36269B105
ISIN:        US36269B1052
Valuation   (See tab for details)
PE ratio:   -6.28
PB ratio:   2.06
PS ratio:   608.70
Return on equity:   -32.83%
Net income %:   -9,356.72%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy